Equity Research Database

Institutional Investment Pitches

Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.

Home Letters Funds Account

Protean Select's investment thesis on Bavarian Nordic A/S ($BAVA.CO) — Q4 2024 | Buyside Digest

All Pitches

View Letter Analysis

$BAVA.CONASDAQBavarian Nordic A/S

BULL

Protean Select—BAVA.CO

Fund Letter

Q4 2024

Published January 7, 2025

View Fund Profile

$175.00USD

-18.8% vs last month

$201.60Pitched

-13.2% since pitch

Market Cap$13.2B

P/E (TTM)N/A

52-Wk RangeN/A

Div. YieldN/A

Technical Chart

From the Fund Letter

Bavarian Nordic's neglected travel vaccine segment, particularly rabies and tick-borne encephalitis (TBE) treatments, provides a highly stable and defensive foundation that mitigates overall risk. TBE vaccines are...

— Pontus Dackmo

BSD Research Exclusive

Unlock Full Institutional Investment Theses

Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.

6,000+ Institutional Pitches

Proprietary AI Analysis

100 Letter Unlocks/Cycle

SUBSCRIBE TO BSD RESEARCH ($55/MO)Compare All Plans

Already a Research or Pro subscriber? Sign In

◆ Keep Reading

What other investors think about $BAVA.CO, and what else Protean Select is buying.

Other pitches on $BAVA.CO

Other investors who've written on Bavarian Nordic A/S

No other institutional pitches found for this ticker yet.

View all $BAVA.CO pitches →